uploads///microscope _

Masimo and Its Peers: Analysts’ Ratings in March 2018

By

Updated

Masimo

Masimo (MASI) is a global medical technology company that focuses on developing, manufacturing, and marketing a variety of noninvasive monitoring technologies. Masimo provides its products directly and through distributors and original equipment manufacturers to hospitals, emergency medical service providers, long-term care facilities, physician offices, veterinarians, and consumers.

Article continues below advertisement

Analysts’ recommendations

Of the five analysts covering Masimo in March 2018, two analysts gave the stock a “strong buy” rating, while three analysts gave it a “hold” rating. The mean rating for the stock is 2.2 with a target price of $99.67.

Peers’ ratings

Of the 24 analysts covering Cerner (CERN) in March 2018, seven analysts gave the stock a “strong buy” rating, four analysts gave it a “buy” rating, and 13 analysts gave it a “hold” rating. The mean rating for the stock is 2.25 with a target price of $71.75.

Of the 20 analysts covering Illumina (ILMN) in March 2018, eight analysts gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, five analysts gave it a “hold” rating, and one analyst gave it a “sell” rating. The mean rating for the stock is 1.95 with a target price of $257.6.

Of the 23 analysts covering Pfizer (PFE) in March 2018, two analysts gave it a “strong buy” rating, ten analysts gave it a “buy” rating, nine analysts gave it a “hold” rating, and two analysts gave it a “strong sell” rating. The mean rating for the stock is 2.57 with a target price of $40.2.

Next, we’ll discuss Masimo’s business strategy.

Advertisement

More From Market Realist